MCID: NRG005
MIFTS: 26

Neurogenic Hypertension malady

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Neurogenic Hypertension

About this section

Aliases & Descriptions for Neurogenic Hypertension:

Name: Neurogenic Hypertension 45 65

Classifications:



External Ids:

UMLS65 C0597048

Summaries for Neurogenic Hypertension

About this section
MalaCards based summary: Neurogenic Hypertension is related to cervicitis and neuronitis, and has symptoms including cushingoid facies An important gene associated with Neurogenic Hypertension is ACE2 (Angiotensin I Converting Enzyme 2), and among its related pathways are Peptide hormone metabolism and Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics. Affiliated tissues include kidney, brain and spinal cord.

Related Diseases for Neurogenic Hypertension

About this section

Diseases related to Neurogenic Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 13)
idRelated DiseaseScoreTop Affiliating Genes
1cervicitis9.9
2neuronitis9.9
3cerebritis9.8
4atherosclerosis9.7
5sleep apnea9.7
6obstructive sleep apnea9.7
7renal hypertension9.7
8cerebral atherosclerosis9.7
9porphyria9.7
10thyroiditis9.7
11hypoxia9.7
12syncope9.7
13neuroma biliary tract9.5ACE2, ENPEP

Graphical network of diseases related to Neurogenic Hypertension:



Diseases related to neurogenic hypertension

Symptoms for Neurogenic Hypertension

About this section

UMLS symptoms related to Neurogenic Hypertension:


cushingoid facies

Drugs & Therapeutics for Neurogenic Hypertension

About this section

Drugs for Neurogenic Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Antibiotics, AntitubercularPhase 35971
2Anti-Bacterial AgentsPhase 3, Phase 1, Phase 29140
3Omega 3 Fatty AcidNutraceuticalPhase 3912
4carnitineNutraceuticalPhase 3146
5
FesoterodineapprovedPhase 260286930-03-86918558
Synonyms:
FESO
 
Fesoterodine
Fesoterodine Fumarate
Toviaz
6
Minocyclineapproved, investigationalPhase 1, Phase 217310118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
Arestin
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
Dynacin
HMS2090D03
HSDB 3130
LMPK07000002
 
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline
Minocycline (USAN/INN)
Minocycline Hydrochloride
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
NCGC00178854-01
NSC 141993
NSC141993
Solodyn
UNII-FYY3R43WGO
Vectrin (Hydrochloride)
Ximino
minociclinum
minocycline
nchembio.559-comp1
7Anti-Infective AgentsPhase 1, Phase 217220
8Neurotransmitter AgentsPhase 214795
9Cholinergic AntagonistsPhase 21423
10Cholinergic AgentsPhase 23243
11Muscarinic AntagonistsPhase 2961

Interventional clinical trials:

idNameStatusNCT IDPhase
1Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in ChildrenRecruitingNCT02192580Phase 3
2L-carnitine on the Prevention of Renal Scarring in Acute PyelonephritisRecruitingNCT02007889Phase 3
3Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)RecruitingNCT02676154Phase 2
4Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive PatientsNot yet recruitingNCT02133885Phase 1, Phase 2
5Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive PatientsRecruitingNCT02133872Phase 1
6Study 3: Minocycline Decreases Microglia ActivationNot yet recruitingNCT02213575Phase 1
7Adolescent Blood Pressure Variation and Ventricular MassCompletedNCT00005200
8Brain fMRT In Takotsubo CardiomyopathyRecruitingNCT02240056

Search NIH Clinical Center for Neurogenic Hypertension

Genetic Tests for Neurogenic Hypertension

About this section

Anatomical Context for Neurogenic Hypertension

About this section

MalaCards organs/tissues related to Neurogenic Hypertension:

33
Kidney, Brain, Spinal cord, Liver, Prostate, Breast, Thyroid

Animal Models for Neurogenic Hypertension or affiliated genes

About this section

Publications for Neurogenic Hypertension

About this section

Articles related to Neurogenic Hypertension:

(show top 50)    (show all 133)
idTitleAuthorsYear
1
In silico Therapeutics for Neurogenic Hypertension and Vasovagal Syncope. (26834545)
2015
2
Brain-targeted angiotensin-converting enzyme 2 overexpression attenuates neurogenic hypertension by inhibiting cyclooxygenase-mediated inflammation. (25489058)
2015
3
Visualizing oxidative stress-induced depression of cardiac vagal baroreflex by MRI/DTI in a mouse neurogenic hypertension model. (23747290)
2013
4
Brain angiotensin-converting enzyme type 2 shedding contributes to the development of neurogenic hypertension. (24014829)
2013
5
Stabilization of hypoxia inducible factor-1I+ ameliorates acute renal neurogenic hypertension. (24309492)
2013
6
Neurogenic hypertension: revelations from genome-wide gene expression profiling. (22639016)
2012
7
Neuroinflammation and oxidative stress in rostral ventrolateral medulla contribute to neurogenic hypertension induced by systemic inflammation. (22958438)
2012
8
Neurogenic hypertension and elevated vertebrobasilar arterial resistance: is there a causative link? (22562144)
2012
9
Contributions of vascular inflammation in the brainstem for neurogenic hypertension. (21601658)
2011
10
Coupling between respiratory and sympathetic activities as a novel mechanism underpinning neurogenic hypertension. (21445721)
2011
11
Global identification of the genes and pathways differentially expressed in hypothalamus in early and established neurogenic hypertension. (21487032)
2011
12
Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. (19926873)
2010
13
Inflammation and neurogenic hypertension: a new role for the circumventricular organs? (20651292)
2010
14
Transcriptional upregulation of mitochondrial uncoupling protein 2 protects against oxidative stress-associated neurogenic hypertension. (19762685)
2009
15
Do changes in the coupling between respiratory and sympathetic activities contribute to neurogenic hypertension? (19413588)
2009
16
Is neurogenic hypertension related to vascular inflammation of the brainstem? (18585782)
2009
17
Signalling across the blood brain barrier by angiotensin II: novel implications for neurogenic hypertension. (18443753)
2008
18
Aminopeptidase A: could it be a novel target for neurogenic hypertension? (18362227)
2008
19
Effect of renal injury-induced neurogenic hypertension on NO synthase, caveolin-1, AKt, calmodulin and soluble guanylate cyclase expressions in the kidney. (17122386)
2007
20
Neurovascular compression of the medulla: can it cause neurogenic hypertension? (17215662)
2007
21
Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. (12052849)
2002
22
Unloading arterial baroreceptors causes neurogenic hypertension. (11893608)
2002
23
Microvascular decompression of the left lateral medulla oblongata for severe refractory neurogenic hypertension. (10069614)
1999
24
Microvascular decompression of the left lateral medulla oblongata for severe refractory neurogenic hypertension. (10515496)
1999
25
Neurogenic hypertension. (8421217)
1993
26
Urinary kallikrein excretion in neurogenic hypertension in the dogs: possible relationship between kallikrein excretion and catecholamines. (2692416)
1989
27
Forebrain mechanisms in neurogenic hypertension. (3690390)
1987
28
Relationship between arterial blood pressure and plasma norepinephrine levels in a patient with neurogenic hypertension. (3799645)
1986
29
Circulating and tissue catecholamines in rats with chronic neurogenic hypertension. (3718427)
1986
30
Neurogenic hypertension: etiology and surgical treatment. II. Observations in an experimental nonhuman primate model. (4015232)
1985
31
Hemodynamic and neural mechanisms of acute neurogenic hypertension in the rat. (6507647)
1984
32
Central serotonergic activity after neurogenic hypertension. (6832215)
1983
33
Norepinephrine release and vascular response elicited by nerve stimulation in rats with chronic neurogenic hypertension. (6312017)
1983
34
Neurogenic hypertension after depletion of norepinephrine in anterior hypothalamus induced by 6-hydroxydopamine administration into the ventral pons: role of serotonin. (6405300)
1983
35
Presynaptic dopamine receptor stimulation and the antihypertensive action of pergolide in experimental neurogenic hypertension. (7122527)
1982
36
Naloxone and acute neurogenic hypertension in anaesthetized dogs. (7138086)
1982
37
The nucleus tractus solitarius and experimental neurogenic hypertension: evidence for a central neural imbalance hypothesis of hypertensive disease. (7010944)
1981
38
Aortic histomine syntesis in experimental neurogenic hypertension. (1129333)
1975
39
The central nervous system and neurogenic hypertension. (4600581)
1974
40
Altered norepinephrine synthesis of splanchnic vessels in neurogenic hypertension. (4152768)
1974
41
Effects of p-chlorophenylalanine on blood pressure and heart rate in normal rabbits and rabbits with neurogenic hypertension. (4282070)
1974
42
What is hypertension? Recent studies on neurogenic hypertension. (4929434)
1971
43
Hemodynamic characteristics of chronic experimental neurogenic hypertension in unanesthetized dogs. (5786795)
1969
44
Aorta wall electrolytes in hypertensive rats. The effect of saline and neurogenic hypertension. (13949962)
1962
45
Arterial hypertension in dogs. II. The effects of neurogenic hypertension with a study of periodic renal biopsies over a seven-year period. (13279130)
1956
46
Experimental psycho-neurogenic hypertension and its treatment with hydrogenated ergot alkaloids (hydergine). (13339143)
1956
47
Role of the adrenals and the hypophysis in experimental neurogenic hypertension. (13305581)
1955
48
Neurogenic hypertension in man in porphyria: transient hypertension and tachycardia caused by disruption of the carotid sinus; review of buffer nerve mechanism. (13170848)
1954
49
The role of the adrenals in experimental neurogenic hypertension. (13093058)
1953
50
Blood Pressure of Renal and of Early and Late Neurogenic Hypertension Dogs after Low Cervical Cord Section. (17858716)
1945

Variations for Neurogenic Hypertension

About this section

Expression for genes affiliated with Neurogenic Hypertension

About this section
Search GEO for disease gene expression data for Neurogenic Hypertension.

Pathways for genes affiliated with Neurogenic Hypertension

About this section

GO Terms for genes affiliated with Neurogenic Hypertension

About this section

Sources for Neurogenic Hypertension

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet